FUNDAMENTALS · Fundamentals · US Consumer Cyclical

Medifast (MED) Fundamentals 2026 — Revenue Analysis | SniperIQ

Medifast (MED) is a US-listed Consumer Cyclical company in Specialty Business Services with a market capitalization of

13M, trading at
0.17 on the NYSE. This SniperIQ fundamentals page covers Medifast's valuation, profitability (net margin -5.8%), revenue (
86M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
13M
Net Margin-5.8%
Revenue (FY25)
86M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Medifast's market cap?

Medifast (MED) has a market capitalization of approximately

13M, trading at
0.17 on the NYSE. Market cap moves with the live share price.

What is Medifast's P/E ratio?

Medifast's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Consumer Cyclical sector peers rather than read in isolation.

How profitable is Medifast?

Medifast runs a net profit margin of -5.8%, a gross margin of 70.1%, and an operating margin of -4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Medifast generate?

Medifast reported revenue of

86M for fiscal year 2025, with net income of -
9M and earnings per share (EPS) of -1.7. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Medifast pay a dividend?

Medifast does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Medifast financially healthy?

Medifast carries a debt-to-equity ratio of 0.08x and a current ratio of 4.80x, with a market beta of 0.68. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Medifast a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Medifast (MED) the key facts are: market cap

13M, revenue
86M, 52-week range 9.22-15.37. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Cyclical peers and form your own view.

Track Medifast's full fundamentals live

Get Medifast's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Tilly's (TLYS) fundamentals · InNature (5295) fundamentals · Lakeland Industries (LAKE) fundamentals · GreenTree Hospitality Group (GHG) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons